Abstract: The invention relates to a process for the preparation of ascorbic acid-2-phosphate, which comprises reacting ascorbic acid or araboascorbic acid with ATP to produce ascorbic acid-2-phosphate in an aqueous medium in the presence of an effective amount of an enzyme derived from a microorganism and capable of catalyzing the enzymatic reaction of ascorbic acid or araboascorbic acid with ATP to produce ascorbic acid-2-phosphate and recovering the resultant ascorbic acid-2-phosphate from the reaction solution.

Abstract: A process for the preparation of ascorbic acid-2-phosphate, which comprises reacting ascorbic acid or araboascorbic acid with a phosphate donor other than ATP in an aqueous medium in the presence of an effective amount of an enzyme derived and capable of preferentially catalyzing the enzymatic phosphorylation in the 2-position of ascorbic acid or araboascorbic acid by said phosphate donor, and recovering the resultant ascorbic acid-2-phosphate from the reaction solution.

Abstract: Compounds comprising a linear .beta.1.fwdarw.6 glucan esterified by caproic acid, the number of D-glucose residues being from 7 to 40 and the number of caproic acid residues being from 2 to 30, may be be obtained by fermentation of a microorganism of the genus Aureobasidium. These compounds are designated HS-142-1. Preferred microorganism is Aureobasidium pullulans var. melanigenum KAC-2383 (FERM-BP 2407).The compounds of the present invention exhibit excellent antagonistic activity to ANP and are capable of inhibiting the bonding of ANP to ANP receptors.

Abstract: Compounds UCF1 and derivatives thereof exhibit anti-bacterial and anti-tumor activities and may be used for the preparation of anti-bacterial and anti-tumor agents.Compounds UCF1 may be produced by fermentation of a microorganism of the genus Streptomyces capable of producing compounds UCF1, preferably Streptomyces sp. UOF1 (FERM BP-2844) and recovering the desired compounds from the cultured broth.The compounds UCF1 have the formula ##STR1## wherein R represents either ##STR2## The compounds may be oxidized to obtain derivatives of formula ##STR3## which exhibit similar pharmacological activities.

Abstract: Mitomycin derivatives containing substituted dithioethylamino groups at the 7th position are provided. The mitomycin derivatives according to the present invention are superior to mitomycin C with respect to their improved anti-tumour activity and toxicity. More particularly, they exhibit a wider tolerance of dosage against Sarcoma 180A solid tumour as well as a better survival time and weaker bone marrow supression against P388.Furthermore, certain compounds exhibit a high water-solubility which is advantageous for pharmaceutical purposes. Excellent anti-tumour agents may readily be prepared by using the derivatives of the present invention.

Abstract: The present invention relates to a compound designated "DC114-C" having excellent anti-bacterial and anti-tumor activities. This compound may be obtained by fermentation of a microorganism of the genus Streptomyces, preferably Streptomyces sp. DO-114 (FERM BP-2641).

Abstract: A process for modifying the properties of egg yolk, which comprises treating egg yolk with an effective amount of phospholipase D derived from a microorganism, thereby to convert phospholipids contained in said egg yolk into phosphatidic acid.

Abstract: A coating agent for delaying the release of a physiologically active substance to be administered per os to ruminants, said coating comprising a veterinary acceptable water-soluble, synthetic high molecular compound and ethylcellulose, said coating agent being stable in the first stomach or rumen of ruminants and capable of being effectively disintegrated for subsequent absorption in the 4th stomach of ruminants, characterized in that said coating agent further comprises at least one substance which is miscible with both of said high molecular weight compound and ethylcellulose and is insoluble in water.Said coating agent forms a coat which protects the active substance from degradation in the first stomach of a ruminant at a pH of about 5.5 and rapidly breaks down in the 4th stomach at a pH of about 3, thereby releasing the active ingredient for absorption by the animal.The coating agent and the actives coated therewith and their preparation are described.

Abstract: Mitomycin derivatives having the formula ##STR1## wherein X is acyl, lower alkyl, alkoxycarbonyl aryloxycarbonyl or aralkoxycarbonyl;Y is hydrogen or methyl;Z is hydrogen, methyl, acyl or allyloxycarbonyl;one of R.sub.1 and R.sub.2 represents carbamoyloxymethyl and the other represents hydrogen, or R.sub.1 and R.sub.2 together represent methylene, show antibacterial and antitumor activities.

Abstract: Compounds of the general formula ##STR1## wherein: X is halogen or trifluoromethyl;R.sub.1 is hydrogen, halogen or trifluoromethyl;R.sub.2 is hydrogen methyl or hydroxymethyl;R.sub.3 is hydrogen or lower alkyl; andY is methylene, methylene substituted with a lower alkyl or hydroxyl group, sulfinyl, sulfonyl, oxygen or sulfur, exhibit a cerebral protective effect and are applicable to the treatment of cerebral ischaemia and cerebral hypoxia.The compounds may be made by acylating a suitable piperidine or morpholine with the appropriate cinnamoyl chloride, and if necessary oxidizing the reaction product.

Abstract: Compounds having analgesic activity which have the formula ##STR1## wherein R.sub.1 -R.sub.6 represent hydrogen or a substituent and X and Y together represent inter alia as epoxyethylene, ethylene halohydrin, haloethylene or a --CH.dbd.CH-group.

Abstract: High-yielding hybridoma cell lines which secrete monoclonal antibodies capable of binding to tumor cells of one or more types, but not normal cells can be obtained more readily by fusing myeloma cells with antibody-forming cells isolated from an animal immunized with tumor antigens, which has previously been made immunological tolerant to normal cell antigens, comprising the total antigens, or at least a proportion of the total antigens, of the normal cells corresponding to the tumor cells chosen as the source of immunizing antigens.

Abstract: Mitomycin derivatives having potent anti-tumor activity having the formula: ##STR1## wherein one of R.sub.1 and R.sub.2 represents carbamoyloxymethyl and the other represents hydrogen or R.sub.1 and R.sub.2 are bonded together to form methylene;X is hydrogen or halogen;Y is hydrogen or methyl;Z is hydrogen, methyl or acyl; andn is an integer of 2 or 3.

Abstract: Compounds of the general formula ##STR1## wherein: X is halogen or trifluoromethyl;R.sub.1 is hydrogen, halogen or trifluoromethyl;R.sub.2 is hydrogen, methyl or hydroxymethyl;R.sub.3 is hydrogen or lower alkyl; andY is methylene, methylene substituted with a lower alkyl or hydroxyl group, sulfinyl, sulfonyl, oxygen or sulfur, exhibit a cerebral protective effect and are applicable to the treatment of cerebral ischaemia and cerebral hypoxia.The compounds may be made by acylating a suitable piperidine or morpholine with the appropriate cinnamoyl chloride, and if necessary oxidizing the reaction product.

Abstract: Mitomycin compound having potent antitumour activity having the formula: ##STR1## wherein ##STR2## (wherein Ra, Rb and Rc each independently represent lower alkyl, cycloalkyl having 3-7 carbon atoms or phenyl; or Ra and Rb are bonded together to form a poly-methylene group having 2-5 carbon atoms);one of R.sub.1 and R.sub.2 represents carbamoyloxymethyl and the other represents hydrogen; or R.sub.1 and R.sub.2 may together form an exocyclic methylene group;and Y and Z each independently represents hydrogen or methyl.

Abstract: Mitomycin derivatives having potent antitumour activity have the formula: ##STR1## wherein R represents lower alkyl, cycloalkyl or unsubstituted or substituted aralkyl;X represents hydrogen or carbamoyl;Y and Z each independently represents hydrogen or methyl;and represents an .alpha. or .beta. bond.

Abstract: Mitomycin derivatives having potent antitumor activity having the formula: ##STR1## wherein A is ON--or R.sub.4 N.dbd.N--[wherein R.sub.4 is selected from ##STR2## and optionally substituted heterocyclic groups (wherein R.sub.5 and R.sub.8 are each independently selected from hydrogen, lower alkyl and lower cycloalkyl; R.sub.6 is selected from hydrogen, halogen, hydroxy, lower alkoxy, amino and nitro; R.sub.7 is selected from lower alkyl and lower cycloalkyl; and X is selected from oxygen, sulphur and imino)];R.sub.1 and R.sub.2 are each independently selected from hydrogen, lower alkyl, lower cycloalkyl, optionally substituted aralkyl, optionally substituted alkanoyl, optionally substituted arylcarbonyl, optionally substituted alkanesulfonyl, arylsulfonyl and aralkylsulfonyl;R.sub.3 is hydrogen or carbamoyl;Y is hydrogen or methyl;Z is selected from hydrogen, methyl and acetyl;and is an .alpha. or .beta. bond.

Abstract: Mitomycin derivatives of the formula: ##STR1## wherein X is ##STR2## [wherein R.sub.3 is alkyl, cycloalkyl or optionally substituted phenyl; and R.sub.4 is alkyl or cycloalkyl]; n is an integer of 2 to 8; one of R.sub.1 and R.sub.2 is a hydrogen atom and the other is a carbamoyloxymethyl group, or alternatively R.sub.1 and R.sub.2 may be combined together to form a methylene group (.dbd.CH.sub.2); and Y and Z independently represent hydrogen or methyl;exhibit anti-bacterial and anti-tumor activities.

Abstract: L-tryptophan can be prepared in good yield by a fermentation process which comprises culturing a novel L-tryptophan-producing microorganism of the genus Corynebacterium, which is resistant to at least one member selected from glyphosate [N-phosphonomethyl glycine], paraquat [1,1'-dimethyl-4,4'-bispyridinium] and derivatives thereof, and recovering L-tryptophan from the culture broth.

Abstract: A new substance K-259-2 having a molecular formula of C.sub.21 H.sub.18 O.sub.7, a molecular weight of 382 and an elemental analysis (%) of H: 4.50, C: 65.53 and N: 0. This substance is of interest in providing a new vasodilating agent in view of its ability to dilate the blood vessel, particularly the artery, of mammals. This substance may be obtained by fermentation of a microorganism Micromonospora sp. K-259 (FERM BP 569).